BCYC analyst estimates

Bicycle Therapeutics (BCYC) analyst ratings, the average price target and its range, and every firm's latest call.

BCYC analyst ratings and price targets

DateFirmCallTarget
Oct 29, 2026JefferiesBicycle Therapeutics (BCYC) PT Lowered to $10 at Jefferies$10.00
Apr 30, 2026JefferiesBicycle Therapeutics price target lowered to $12 from $13 at Jefferies$12.00
Apr 8, 2026Morgan StanleyBicycle Therapeutics price target lowered to $12 from $13 at Morgan Stanley$12.00
Mar 17, 2026Morgan StanleyMorgan Stanley on Bicycle Therapeutics (BCYC): program deprioritization 'disappointing,' but 'right call'$13.00
Mar 17, 2026Truist FinancialBicycle Therapeutics (BCYC) PT Lowered to $8 at Truist Securities$8.00
Nov 24, 2025Truist FinancialBicycle Therapeutics initiated with a Hold at Truist$10.00
Oct 31, 2025RBC CapitalRBC downgrades Bicycle Therapeutics on slow pipeline progress$11.00
Oct 31, 2025JMP SecuritiesBicycle Therapeutics price target raised to $12 from $10 at Citizens JMP$12.00
Aug 11, 2025RBC CapitalBicycle Therapeutics price target raised to $27 from $25 at RBC Capital$27.00
May 5, 2025Morgan StanleyBicycle Therapeutics price target raised to $17 from $15 at Morgan Stanley$17.00
Dec 18, 2024JMP SecuritiesBicycle Therapeutics price target lowered to $26 from $32 at JMP Securities$26.00
Oct 24, 2024B.Riley FinancialB.Riley Reiterates Neutral Rating on Bicycle Therapeutics (BCYC)$28.00
Oct 24, 2024OppenheimerOppenheimer Reiterates Outperform Rating on Bicycle Therapeutics (BCYC)$48.00
Sep 16, 2024H.C. WainwrightH.C. Wainwright Reiterates Buy Rating on Bicycle Therapeutics (BCYC)$55.00
Oct 7, 2021Piper SandlerBicycle Therapeutics price target raised to $76 from $46 at Piper Sandler$76.00